United Therapeutics Corporation (UTHR)
UTHR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/0001082554-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | UTHR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 1999 |
| SEC CIK | 0001082554 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.2B |
| Net income | $1.3B |
| Operating income | $1.5B |
| Net margin | 41.9% |
| Operating margin | 46.9% |
| Revenue growth | +10.6% |
| Cash | $1.6B |
| Total assets | $7.9B |
| P/E (computed) | 18.8× |
| P/S (computed) | 7.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $1.2B cash; operating cash flow $357.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 42,588,726 (2026-10-28); 43,056,599 a year earlier; 46,993,601 three years earlier. | Cover page 2026-10-28 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Tysons, Virginia, United States | PCAOB Form AP 2026-03-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $864K, sold $1.4B on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $832.5M | $258.6M | $306.5M | $1.2B | No debt tags | $3.2B | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $783.3M | $333.0M | $313.6M | $1.8B | No debt tags | $3.2B | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $781.5M | $274.9M | $463.3M | $1.3B | No debt tags | $3.2B | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $790.2M | $364.3M | $346.2M | $1.6B | No debt tags | $3.2B | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $799.5M | $338.7M | $562.1M | $1.3B | No debt tags | $3.1B | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $798.6M | $309.5M | $191.7M | $1.6B | No debt tags | $3.1B | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $794.4M | $322.2M | $461.2M | $1.9B | No debt tags | $3.0B | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $735.9M | $301.3M | $341.2M | $1.7B | No debt tags | $2.9B | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.2% |
| 1 month | +8.8% |
| 3 months | +17.9% |
| Year to date | +21.3% |
| 1 year | +27.9% |
| From 52-week high | -2.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VTRS | Viatris Inc. | $20.74 | -0.38% | $23.8B |
| INSM | Insmed Incorporated | $122.88 | +1.42% | $27.0B |
| ROIV | Roivant Sciences Ltd. Common Shares | $38.61 | -2.33% | $28.0B |
| ALNY | Alnylam Pharmaceuticals Inc. | $159.73 | -3.22% | $21.4B |
| GMAB | Genmab A/S ADS | $51.57 | +0.39% | $32.2B |
| ZTS | Zoetis Inc. | $84.39 | +0.68% | $34.3B |
| ASND | Ascendis Pharma A/S Ordinary Share | $271.73 | -1.33% | $17.9B |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | $68.53 | -1.13% | $39.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier